PTC Therapeutics: Sephience Turns The Story From Regulatory Repair To Operating Leverage

PTC Therapeutics is transitioning from a legacy rare disease business to a growth-focused model, anchored by the successful Sephience launch. Sephience's rapid commercial uptake is offsetting DMD franchise declines, with Q1 2026 product revenue up 47% year-over-year and strong patient onboarding momentum. PTCT's partnership with Novartis on votoplam for Huntington's disease offers de-risked late-stage upside, while a $1.9B cash position provides strategic flexibility and reduces near-term dilution risk.